Cholesterol-lowering drugs not associated with increased breast cancer risk

May 16, 2006

PITTSBURGH- A report being published in the Journal of the National Cancer Institute found that women who took statins--the widely used cholesterol lowering drugs--do not face an increased breast cancer risk as had been suggested by some previous studies. In fact, the study, which was led by a researcher at the University of Pittsburgh Graduate School of Public Health (GSPH), found that women who took hydrophobic statins, named for their inability to dissolve readily in water, had an almost one-fifth lower incidence of invasive breast cancer compared to women who did not take statins.

"At minimum, our findings suggest that women can now be reassured that they are not increasing their risk of developing breast cancer by taking these drugs," said senior author Jane Cauley, Dr.P.H., professor and vice chair for research, department of epidemiology, GSPH. "Although we found that women who took hydrophobic statins actually lowered their breast cancer risk, we believe this finding needs to be confirmed in additional studies."

Dr. Cauley and her co-workers, representing several other research institutions, obtained their findings by analyzing breast cancer incidence over an almost seven-year period among more than 156,000 women enrolled in the long-running Women's Health Initiative study. Of this group of post-menopausal women, 11,710 were statin users; with about 30 percent taking a hydrophilic, or water soluble, statin, and the remaining 70 percent taking a hydrophobic statin.

During the follow-up period, 4,483 women in the study were diagnosed with invasive breast cancer. When the research team examined statins as a class, they found no statistically significant association between statin use and breast cancer incidence, although statin users did tend to have somewhat lower breast cancer rates than non-statin users. Breast cancer incidence also was not associated with how long statins were used. Moreover, use of post-menopausal hormone therapy did not modify the association between statin use and breast cancer. However, when the investigators analyzed breast cancer rates by type of statin, they found that among women taking any of several hydrophobic statins, there was an 18 percent decreased incidence of breast cancer compared to nonusers of statins and that this difference was statistically significant.

Dr. Cauley notes that finding a link between hydrophobic statins and reduced breast cancer risk is consistent with the results of several other recent studies. One, a cell culture study, found that hydrophobic statins inhibited the growth of several breast cancer cell lines, while a hydrophilic statin did not. In addition, another study reported a 72 percent lower risk of breast cancer in a small group of women, most of whom were taking hydrophobic statins.

"A number of different mechanisms have been identified by which this class of statins might inhibit the growth of cancer. For example, animal studies have shown that hydrophobic statins induce programmed cell death, or apoptosis. Hence, there certainly is some biological plausibility for this class of statins preventing cancer," said Dr. Cauley.

However, she cautions that further research is needed to determine whether hydrophobic statins actually can inhibit breast cancer in humans.

Statins are among the most widely prescribed drugs in the United States, with $12.5 billion in annual sales. In 2004, two statins - atorvastatin and simvastatin - were the No. 1 and No. 2 best-selling drugs in the country, with sales of atorvastatin alone topping 70 million prescriptions. Although highly effective in reducing cholesterol, statins have side effects, including headache, nausea, vomiting, constipation, diarrhea, rash, weakness and muscle pain. The most serious side effects, although rare, are liver failure and permanent muscle damage.
This study was funded by the National Heart, Lung and Blood Institute, National Institutes of Health. In addition to Dr. Cauley, others include Anne McTiernan, M.D., Ph.D., Rebecca J. Rodabough, M.S., and Andrea LaCroix, Ph.D., at the Fred Hutchinson Cancer Research Center; Douglas C. Bauer, M.D., at the University of California, San Francisco; Karen L. Margolis, M.D., at the Hennipen County Medical Center, Minneapolis; Electra D. Paskett, Ph.D., at Ohio State University; Maria Z. Vitolins, Dr.P.H., and Curt D. Furberg, M.D., Ph.D., at Wake Forest University; and Rowan T. Chlebowski, M.D., at Harbor-UCLA Medical Center.

Founded in 1948 and fully accredited by the Council on Education for Public Health, GSPH is world-renowned for contributions that have influenced public health practices and medical care for millions of people. One of the top-ranked schools of public health in the United States, GSPH was the first fully accredited school of public health in the Commonwealth of Pennsylvania, with alumni who are among the leaders in their fields of public health. A member of the Association of Schools of Public Health, GSPH currently ranks third among schools of public health in NIH funding received. The only school of public health in the nation with a chair in minority health, GSPH is a leader in research related to women's health, HIV/AIDS and human genetics, among others. For more information about GSPH, visit the GSPH Web site at

University of Pittsburgh Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to